Qiagen
VC Fund
Venlo, The Netherlands
Qiagen is a VC fund in Venlo focused on Biotechnology and Life Science. QIAGEN N.V., through its subsidiaries, provides technologies and products for preanalytical sample preparation and linked molecular assay solutions. The company also supplies diagnostic kits, tests, and assays for human and veterinary molecular diagnostics. Technologies Sample Technologies: The company’s sample technologies provide access to thecontent of biological samples. These include solutions for the collection, stabilization, purification, handling and storage of any analyte (deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and protein) from any sample (blood, bone, and tissue). Assay Technologies: The company’s assay technologies include reagents which enable the detection of such purified target analytes, such as the DNA sequence from a specific virus, from a purified sample. It also provided closed assays, in which such assay technologies have been pre-configured to test for specific targets, such as the influenza virus, hepatitis, HIV, HPV or herpes. Products The company has developed a portfolio of approximately 500 proprietary, consumable products, and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification, as well as open and target specific assays. The main categories of its products include: Consumables: The company’s consumable products include its sample and assay technologies. Sample technologies are used to collect, stabilize, isolate and purify DNA, RNA and proteins from biological samples, such as blood or tissue. Assay technologies like its amplification consumables or molecular diagnostic assays are used to make such isolated biomolecules visible. The company offers its sample and assay consumable products in kit form. These kits contain necessary reagents and buffers, and a technical handbook that includes a protocol and background information. Major applications for the company’s consumable products are plasmid, DNA purification; RNA purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; DNA cloning and protein purification. It offers validated PCR assays which allow PCR-based detection of viral, bacterial and parasite, human and animal pathogens, as well as pharmacogenomic genotyping. In 2007, the company acquired Digene Corporation and began offering the HC2 HPV Test, a signal amplified test for the Human Papillomavirus for use in cervical cancer screening programs. Instrumentation: The company’s automated systems automate the consumables in low, medium or high throughput scale, as well as reaction set-up, allowing customers to perform low- to high-throughput nucleic acid sample preparation, assay setup and other laboratory tasks. The company’s automated systems offer walk-away automation of sample and assay technologies in low, medium or high throughput scale, as well as reaction set-up and other laboratory tasks.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Qiagen invests in
Stages Qiagen invests in
Countries Qiagen invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Investment Focus
Industry
- Biotechnology 4 (100%)
- Life Science 2 (50%)
- Medical 1 (25%)
- Biopharma 1 (25%)
- Health Care 1 (25%)
Stage
- Seed 1 (25%)
- Grant 1 (25%)
- Series B 1 (25%)
- Funding Round 1 (25%)
Country
- Germany 2 (50%)
- United States 2 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Carsten Knaut
Head of HR (Digital) Transformation
|
Head of HR (Digital) Transformation | Total investments: 0 | Find email | |
David Heffelfinger
Site Manager & Sr. Director of Engineering
|
Site Manager & Sr. Director of Engineering | Total investments: 0 | Find email | |
Marta Herreros
Clinical Study Lead
|
Clinical Study Lead | Total investments: 0 | Find email | |
|
Metin Colpan
Founder & CEO
|
Founder & CEO | Total investments: 0 | Find email | |
Reinhard Ortmann
Director Companion Diagnostics
|
Director Companion Diagnostics | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biologyand disease. | $40K / Grant / Jan 19, 2022 | ||
| Actome focuses on developing emulsion coupling technology for life science research and personalized medicine. | Seed / Jul 01, 2021 | ||
| Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others. | $11M / Dec 17, 2014 | ||
| Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changedits name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc. | $12.9M / Series B / Aug 03, 1999 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Qiagen invest in?
Qiagen invests primarily in Biotechnology, Life Science and Medical startups, most often at Seed and Grant stage. Most of the 4 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Qiagen?
Public channels for Qiagen include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Qiagen?
The team at Qiagen includes Carsten Knaut (Head of HR (Digital) Transformation), David Heffelfinger (Site Manager & Sr. Director of Engineering) and Marta Herreros (Clinical Study Lead), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
